Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascentage Acquires Global Rights to Protein Degrader Technology

publication date: Nov 30, 2020

Suzhou's Ascentage Pharma acquired global rights to a MDM2 protein degrader developed at the University of Michigan. Ascentage will have exclusive rights to the Proteolysis-Targeting Chimeras (PROTACs) technology that uses the ubiquitin-proteasome system to induce degradation of targeted proteins. The lead drug candidate is currently entering IND-enabling studies. Previous MDM2 inhibitors block MDM2-p53 interactions and restore the tumor-suppressing activity of p53, but they have drawbacks, including dose-limiting toxicities. MDM2-driven tumors include leukemia. More details....

Stock Symbol: (HK: 6855)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.